JP6474941B2 - 物質を骨内に送達する装置 - Google Patents
物質を骨内に送達する装置 Download PDFInfo
- Publication number
- JP6474941B2 JP6474941B2 JP2018512417A JP2018512417A JP6474941B2 JP 6474941 B2 JP6474941 B2 JP 6474941B2 JP 2018512417 A JP2018512417 A JP 2018512417A JP 2018512417 A JP2018512417 A JP 2018512417A JP 6474941 B2 JP6474941 B2 JP 6474941B2
- Authority
- JP
- Japan
- Prior art keywords
- bone
- deposition
- tissue
- kit
- localized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000988 bone and bone Anatomy 0.000 title claims description 91
- 239000000463 material Substances 0.000 title claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 34
- 230000008021 deposition Effects 0.000 claims description 30
- 238000002604 ultrasonography Methods 0.000 claims description 28
- 238000009792 diffusion process Methods 0.000 claims description 14
- 238000012384 transportation and delivery Methods 0.000 claims description 8
- 230000004807 localization Effects 0.000 claims description 7
- 230000017531 blood circulation Effects 0.000 claims description 5
- 230000010412 perfusion Effects 0.000 claims description 4
- 230000003044 adaptive effect Effects 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 239000002086 nanomaterial Substances 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000000151 deposition Methods 0.000 description 24
- 229940079593 drug Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 206010017076 Fracture Diseases 0.000 description 10
- 230000032258 transport Effects 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 8
- 208000010392 Bone Fractures Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 210000004872 soft tissue Anatomy 0.000 description 5
- 208000020084 Bone disease Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008468 bone growth Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000006735 Periostitis Diseases 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 210000003460 periosteum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001022 anti-muscarinic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- -1 steroids) Chemical class 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 238000012285 ultrasound imaging Methods 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000003933 gonadotropin antagonist Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 239000002073 nanorod Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940035677 psycholeptics Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/88—Osteosynthesis instruments; Methods or means for implanting or extracting internal or external fixation devices
- A61B17/8802—Equipment for handling bone cement or other fluid fillers
- A61B17/8805—Equipment for handling bone cement or other fluid fillers for introducing fluid filler into bone or extracting it
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/88—Osteosynthesis instruments; Methods or means for implanting or extracting internal or external fixation devices
- A61B17/885—Tools for expanding or compacting bones or discs or cavities therein
- A61B17/8852—Tools for expanding or compacting bones or discs or cavities therein capable of being assembled or enlarged, or changing shape, inside the bone or disc
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B2017/564—Methods for bone or joint treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/286—Bone stimulation by mechanical vibrations for enhancing ossification
- A61F2002/2864—Bone stimulation by mechanical vibrations for enhancing ossification by ultrasonic or acoustic vibrations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/02—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0013—Fracture healing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgical Instruments (AREA)
- Laser Surgery Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims (11)
- 骨内に物体を送達する物体送達構成と、
標的からの受動拡散を打ち消すように構成される保持手段とを含む、
キットであって、
前記保持手段は、
− 周囲の組織よりも低い灌流係数を有する被覆層、
− 前記骨内の前記標的からの受動拡散を防止するのに十分な大きさを有する能動的な物体、
− 前記骨内の標的部位を拡張し且つ覆う物質、及び
− 該物質の沈着のための機械的な波の適用後に、前記標的内で前記物質を維持するための、機械的な波の後続の適用
のうちの1つによって形成され、
前記構成は、局所化された機械的な波を生成するように構成された超音波源、光音響源、又はプラズマ源を含み、
前記構成は、
骨の近くで前記物体の局所化された沈着を実行し、
前記物体及び前記骨を前記局所化された機械的な波に曝して前記物体を前記骨内に押し込み、且つ、
前記沈着させられる物体が前記骨内の前記標的部位から漏れ出すのを防止するために、前記保持手段を用いることによって、前記骨内での前記沈着させられる物体の保持を実行する、
ように構成される、
キット。 - 前記構成は、前記骨内への前記物体の沈着を得るために、前記骨に前記物体を輸送する手段を含むことを特徴とする、請求項1に記載のキット。
- 前記構成は、拡散のより正確な局所化を達成するために、高強度集束超音波(HIFU)、導波管、波場の電磁操縦、及び前記物体の電磁操縦のうちの少なくとも1つに基づいて前記局所化を実行する、前記組織内への局所化された機械的な波を生成する手段を含むことを特徴とする、請求項1に記載のキット。
- 前記構成は、適応集束を実行する時間反転超音波に基づいて組織内への局所化された機械的な波を生成する手段を含むことを特徴とする、請求項1に記載のキット。
- 前記構成は、前記組織の内側で局所化された機械的な波を生成する手段を局所化するために、並びに骨内の超音波エネルギ沈着に対する骨に隣接する組織内の超音波エネルギ沈着を減少させるために、光音響変換に基づいて骨の近くでの前記物体の局所化された沈着を実行する手段を含むことを特徴とする、請求項1に記載のキット。
- 前記構成は、前記物体の貯槽から物体を選択し且つ前記物体を骨組織内に押し込む手段を含むことを特徴とする、請求項1に記載のキット。
- 前記構成は、異なる時点で選択的に物体を活性化させる手段を含むことを特徴とする、請求項1に記載のキット。
- 前記構成は、強化された沈着のために機械的な振動によって標的構造に影響を与える手段を含むことを特徴とする、請求項1に記載のキット。
- 前記構成は、制御拡散及び拡散の増幅のうちの少なくとも1つを達成するナノ構造手段を含むことを特徴とする、請求項1に記載のキット。
- 前記構成は、前記物体の輸送のために骨髄腔及び血液循環のうちの少なくとも1つを利用して前記骨への前記物体の沈着を得るために、前記物体及び前記骨を前記機械的な波に曝す手段を含むことを特徴とする、請求項1に記載のキット。
- 前記構成は、前記物体の輸送及び前記物体の沈着を向上させるために、少なくとも2つの異なる周波数の機械的な波を生成する多中心周波数手段を含むことを特徴とする、請求項1に記載のキット。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/FI2015/050589 WO2017042422A1 (en) | 2015-09-09 | 2015-09-09 | Apparatus for delivery of substances into bone |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018527093A JP2018527093A (ja) | 2018-09-20 |
JP6474941B2 true JP6474941B2 (ja) | 2019-02-27 |
Family
ID=54207543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018512417A Active JP6474941B2 (ja) | 2015-09-09 | 2015-09-09 | 物質を骨内に送達する装置 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20180193075A1 (ja) |
EP (1) | EP3347081B1 (ja) |
JP (1) | JP6474941B2 (ja) |
CN (1) | CN108025165B (ja) |
AU (1) | AU2015408449B2 (ja) |
ES (1) | ES2796236T3 (ja) |
WO (1) | WO2017042422A1 (ja) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11267229A (ja) * | 1998-03-19 | 1999-10-05 | Takeshi Nishisaka | 骨形成装置 |
US6231528B1 (en) | 1999-01-15 | 2001-05-15 | Jonathan J. Kaufman | Ultrasonic and growth factor bone-therapy: apparatus and method |
US9302087B2 (en) * | 2002-02-14 | 2016-04-05 | Gholam A. Peyman | Method and composition for hyperthermally treating cells |
US8551096B2 (en) * | 2009-05-13 | 2013-10-08 | Boston Scientific Scimed, Inc. | Directional delivery of energy and bioactives |
WO2012170909A1 (en) * | 2011-06-10 | 2012-12-13 | The Research Foundation Of State University Of New York | Method and device for non-invasive acoustic stimulation of stem cells and progenitor cells in a patient |
GB201212222D0 (en) * | 2012-07-10 | 2012-08-22 | Univ Dundee | Improved apparatus and method for mineralising biological materials |
US10835767B2 (en) * | 2013-03-08 | 2020-11-17 | Board Of Regents, The University Of Texas System | Rapid pulse electrohydraulic (EH) shockwave generator apparatus and methods for medical and cosmetic treatments |
-
2015
- 2015-09-09 CN CN201580083006.2A patent/CN108025165B/zh active Active
- 2015-09-09 EP EP15771668.9A patent/EP3347081B1/en active Active
- 2015-09-09 WO PCT/FI2015/050589 patent/WO2017042422A1/en active Application Filing
- 2015-09-09 JP JP2018512417A patent/JP6474941B2/ja active Active
- 2015-09-09 AU AU2015408449A patent/AU2015408449B2/en active Active
- 2015-09-09 ES ES15771668T patent/ES2796236T3/es active Active
-
2018
- 2018-03-09 US US15/917,044 patent/US20180193075A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2015408449B2 (en) | 2018-04-12 |
CN108025165A (zh) | 2018-05-11 |
EP3347081A1 (en) | 2018-07-18 |
AU2015408449A1 (en) | 2018-03-22 |
CN108025165B (zh) | 2019-01-01 |
US20180193075A1 (en) | 2018-07-12 |
ES2796236T3 (es) | 2020-11-26 |
EP3347081B1 (en) | 2020-03-04 |
JP2018527093A (ja) | 2018-09-20 |
WO2017042422A1 (en) | 2017-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11534187B2 (en) | Acoustic therapy device | |
US8568339B2 (en) | Single element ultrasound transducer with multiple driving circuits | |
CN109152930A (zh) | 脉冲声波皮肤清理系统和方法 | |
JP2019528807A (ja) | 実体物の抽出および送達のための方法および装置 | |
KR20000068302A (ko) | 초음파 치료장치 | |
JP2003526403A (ja) | 低強度超音波によるキャビテーション誘発組織治療の方法およびキット | |
US20070232987A1 (en) | One-hand-operated ultrasound transducer and method for delivering a controlled and uniform distribution of a sterile or a non-sterile topical reagent to skin for use in diagnostic, therapeutic, and aesthetic therapies | |
Alkins et al. | High-intensity focused ultrasound ablation therapy of gliomas | |
Williams et al. | The histotripsy spectrum: differences and similarities in techniques and instrumentation | |
Watson et al. | Therapeutic ultrasound | |
Nieminen et al. | The potential utility of high-intensity ultrasound to treat osteoarthritis | |
US20200406017A1 (en) | Technique and method to locally deliver objects into bone | |
JP6474941B2 (ja) | 物質を骨内に送達する装置 | |
Tsaklis | Presentation of acoustic waves propagation and their effects through human body tissues | |
US8465427B1 (en) | Combined diagnostic confocal scanning and low intensity ultrasound treatment | |
Feril et al. | Therapeutic potential of low-intensity ultrasound (part 1): thermal and sonomechanical effects | |
JPH07213622A (ja) | 薬剤投与装置 | |
Jose et al. | " THERAPEUTIC ULTRASOUND-A NEW INNOVATIVE THERAPY IN DENTISTRY | |
Ginter et al. | Wolf-innovative piezoelectric shock wave systems: Piezolith 3000 and Piezoson 100 plus | |
JPH11267229A (ja) | 骨形成装置 | |
JPH0698917A (ja) | 悪性腫瘍の超音波細胞膜整合振動療法 | |
JPH03103250A (ja) | 超音波治療装置 | |
Jeong et al. | Dual-frequency acoustic cavitation for noninvasively breaking down a cataractous lens | |
WO2004100850A2 (en) | Method of applying gas contact ultrasound therapy, surgery, and drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20180307 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180307 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20180307 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20180727 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180807 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190108 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190130 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6474941 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |